Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 2.1 USD -7.49% Market Closed
Market Cap: 2.1B USD

Wall Street
Price Targets

IBRX Price Targets Summary
Immunitybio Inc

Wall Street analysts forecast IBRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IBRX is 10.61 USD with a low forecast of 5.05 USD and a high forecast of 25.2 USD.

Lowest
Price Target
5.05 USD
140% Upside
Average
Price Target
10.61 USD
405% Upside
Highest
Price Target
25.2 USD
1 100% Upside
Immunitybio Inc Competitors:
Price Targets
GLTO
Galecto Inc
26% Upside
EDT
Spectral Medical Inc
149% Upside
FYB
Formycon AG
102% Upside
ACAD
ACADIA Pharmaceuticals Inc
8% Upside
IONS
Ionis Pharmaceuticals Inc
9% Upside
MRSN
Mersana Therapeutics Inc
17% Upside
VCYT
Veracyte Inc
15% Upside
ONCO
Oncopeptides AB
16% Upside

Revenue
Forecast

Revenue Estimate
Immunitybio Inc

For the last 10 years the compound annual growth rate for Immunitybio Inc's revenue is 37%. The projected CAGR for the next 4 years is 187%.

37%
Past Growth
187%
Estimated Growth
Estimates Accuracy
41%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Immunitybio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-77%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IBRX's stock price target?
Price Target
10.61 USD

According to Wall Street analysts, the average 1-year price target for IBRX is 10.61 USD with a low forecast of 5.05 USD and a high forecast of 25.2 USD.

What is Immunitybio Inc's Revenue forecast?
Projected CAGR
187%

For the last 10 years the compound annual growth rate for Immunitybio Inc's revenue is 37%. The projected CAGR for the next 4 years is 187%.

Back to Top